Navigation Links
China Medical Technologies Senior Management Purchased Company Shares
Date:3/6/2009

BEIJING, March 6 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that each of Mr. Xiaodong Wu, the Company's Chairman and Chief Executive Officer, Mr. Sam Tsang, the Company's Chief Financial Officer and Dr. Zhong Chen, the Company's Chief Technology Officer, purchased the Company's American Depositary Shares (''ADSs'') in the open market in the past two days.

Mr. Wu purchased 150,000 ADSs at an average price of US$13.07 per ADS. Mr. Tsang purchased 6,500 ADSs at an average price of US$13.15 per ADS. Dr. Chen purchased 5,000 ADSs at an average price of US$12.81 per ADS.

Mr. Wu has indicated to the Company that he may continue to purchase the Company's ADSs in the open market in the future in compliance with the Company's insider trading policy.

About China Medical Technologies, Inc.

China Medical Technologies is a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic (IVD) products using Enhanced Chemiluminescence (ECLIA) technology, Fluorescent in situ Hybridization (FISH) technology and Surface Plasmon Resonance (SPR) technology to detect and monitor various diseases and disorders. For more information, please visit http://www.chinameditech.com .

    For more information, please contact:

     Winnie Yam
     Tel:   +86-10-6530-8833
     Email: IR@chinameditech.com

'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Bio-Immunity Corporation - Rabies Vaccine Recall
2. China Medicine to Participate in 2009 Natural Products Expo West Trade Show
3. China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets
4. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
5. Dow AgroSciences, China National Rice Research Institute Announce Collaboration on Rice Research
6. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
7. OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
8. China Biologic Products Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
9. China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan
10. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
11. Syngenta Enters Into Research Collaboration With Anhui Academy, China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):